Goodwin, longstanding counsel to Robocath and previously involved in its recent transactions, advised the company on a definitive agreement with Stereotaxis, a publicly listed US medical technology company, for its acquisition.
This transaction further strengthens Stereotaxis’ position as a leading endovascular platform through the integration of complementary technologies supporting next-generation robotic solutions in electrophysiology, interventional cardiology, and neurointerventions.
The acquisition is subject to customary closing conditions and is expected to close in mid-2026. Upon closing, Robocath will operate as a wholly owned subsidiary of Stereotaxis.
Headquartered in Rouen, Robocath has developed the R-One+ system for percutaneous coronary interventions in Europe, with 15 commercial installations worldwide. The company recently performed the first-in-human procedures in France using a next-generation system designed to enable simultaneous manipulation of up to five interventional devices.
The Goodwin team included:
- In France, Anne-Charlotte Rivière, Louis Taslé d’Héliand, and Pauline Louis on corporate matters, Marie Fillon on intellectual property matters, and Marie-Laure Bruneel on tax matters.
- In the US, Tevia Pollard on corporate matters and Folake Ayoola on capital markets matters.